The Launch ofSarcoma

The Launch of Sarcoma

The members of the Editorial Board and I welcome you to the ® rst issue of Sarcoma. This is a specialist journal that I hope will meet the needs of all who are interested in this group of diseases. The aim of this journal is to provide a focus and forum for all involved in sarcoma research. This includes scientists and clinicians and stretches from molecular biology through pathology, radiology...

The launch of MCBEND 10.

MCBEND 10 is the latest release of the general radiation transport Monte Carlo code from the ANSWERS Software Service of Serco Assurance. MCBEND is developed within a Nuclear Code Development (NCD) partnership between Serco Assurance and BNFL. The ANSWERS vision is 'to provide easy-to-use software that meets the current and emerging needs of the user community'. In the case of MCBEND, this visi...

Launch of the 'New Journal'

A successful launch.

One year ago, the American Society for Clinical Investigation (ASCI) launched JCI Insight. I am pleased to report that the last year has been a resounding success for the Society’s newest journal. Let me begin with some background. In my inaugural editorial, I laid out the rationale for JCI Insight (1). In brief, its mission is two-fold: to provide an additional forum for ASCI members and other...

Failure to Launch

Ma The importance of inflammation and inflammatory pathways in atherosclerotic disease and acute coronary syndromes (ACS) is well established. The success of statin therapy rests not only on potently reducing levels of low-density lipoprotein cholesterol, but also on the many beneficial, pleiotropic effects statin therapy has on various inflammatory mechanisms in atherosclerotic disease, from r...